Clinical Trial Update: Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1 [EARLY_Phase 1]

View source ↗

Summary

An antisense oligonucleotide therapy for FLVCR1-related Posterior Column Ataxia with Retinitis Pigmentosa is in EARLY_PHASE1 and currently enrolling by invitati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posterior Column Ataxia with Retinitis Pigmentosa

Drugs mentioned

• Antisense oligonucleotide therapy targeting FLVCR1 (PCARP) (unspecified)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Posterior Column Ataxia with Retinitis Pigmentosa | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION